2. Search Result
Search Result
Results for "

memory impairment

" in MedChemExpress (MCE) Product Catalog:

52

Inhibitors & Agonists

6

Peptides

5

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-151518
    Aminopeptidase-IN-1

    		Aminopeptidase Neurological Disease
    Aminopeptidase-IN-1 (compound 16o) is a potent insulin-regulated aminopeptidase (IRAP) inhibitor with an Ki value of 7.7 μM. Aminopeptidase-IN-1 can be used tor research cognitive and memory impairments .
    Aminopeptidase-IN-1
  • HY-142066
    4′-Demethylnobiletin

    		PKA ERK iGluR Neurological Disease
    4′-Demethylnobiletin is a bioactive metabolite that activates the PKA/ERK/CREB signaling pathway, enhances CRE-mediated transcription in hippocampal neurons, and reverses memory impairment associated with NMDA receptor antagonism by stimulating ERK signaling .
    4′-Demethylnobiletin
  • HY-W014941
    (R)-(-)-α-Methylhistamine dihydrochloride

    		Histamine Receptor Neurological Disease
    (R)-(-)-α-Methylhistamine dihydrochloride is a potent, selective and brain-penetrant agonist of H3 histamine receptor, with a Kd of 50.3 nM . (R)-(-)-α-Methylhistamine dihydrochloride can enhance memory retention, attenuates memory impairment in rats .
    (R)-(-)-α-Methylhistamine dihydrochloride
  • HY-145831
    sEH/AChE-IN-1

    		Cholinesterase (ChE) Neurological Disease Inflammation/Immunology
    sEH/AChE-IN-1 (Compound 12a) is a dual inhibitor of the enzymes soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE). sEH/AChE-IN-1 provides cumulative effects against neuroinflammation and memory impairment. sEH/AChE-IN-1 has the potential for the research of Alzheimer's disease (AD) .
    sEH/AChE-IN-1
  • HY-145832
    sEH/AChE-IN-2

    		Cholinesterase (ChE) Neurological Disease Inflammation/Immunology
    sEH/AChE-IN-2 (Compound 12b) is a dual inhibitor of the enzymes soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE). sEH/AChE-IN-2 provides cumulative effects against neuroinflammation and memory impairment. sEH/AChE-IN-2 has the potential for the research of Alzheimer's disease (AD) .
    sEH/AChE-IN-2
  • HY-151386
    BChE-IN-13

    		Cholinesterase (ChE) Neurological Disease
    BChE-IN-13 (Compound 17c) is an orally active, potent and selective Butyrylcholinesterase (BChE) inhibitor with IC50s of 0.22 and 0.016 μM for eqBChE and hBChE, respectively. BChE-IN-13 can improve memory and cognitive impairments, and be used in Alzheimer’s disease (AD) research .
    BChE-IN-13
  • HY-156017
    5-HT6R antagonist 1

    		5-HT Receptor Cardiovascular Disease Neurological Disease
    5-HT6R antagonist 1 (Comopund 8) is a 5-HT6R antagonist (Ki: 5 nM). 5-HT6R antagonist 1 inhibits platelet aggregation. 5-HT6R antagonist 1 has excellent metabolic stability. 5-HT6R antagonist 1 reverses MK-801 (HY-15084B)-induced memory impairments in rats. 5-HT6R antagonist 1 can be used for Alzheimer's disease (AD) research .
    5-HT6R antagonist 1
  • HY-120546
    Ulixacaltamide

    Z944

    		 Calcium Channel Neurological Disease
    Ulixacaltamide (Z944) is an orally active T-type calcium channel antagonist that rescues impairments in crossmodal and visual recognition memory.
    Ulixacaltamide
  • HY-I0020
    Galanthaminone

    (-)-Narwedine; Narwedin

    		 Cholinesterase (ChE) Neurological Disease
    Galanthaminone (Narwedin) is a competitive and reversible cholinesterase (AChE) inhibitor; is used for the treatment of mild to moderate Alzheimer's disease and various other memory impairments.
    Galanthaminone
  • HY-P3201
    PKCζ/ι pseudosubstrate inhibitor

    		Pyruvate Kinase Neurological Disease
    PKCζ/ι pseudosubstrate inhibitor has broad-spectrum effects on the PKC enzyme family and can induce memory impairment .
    PKCζ/ι pseudosubstrate inhibitor
  • HY-100999
    (R)-(-)-α-Methylhistamine dihydrobromide

    (R)-(-)-α-Methylhistamine dihydrobromide is a potent, selective and brain-penetrant agonist of H3 histamine receptor, with a Kd of 50.3 nM . (R)-(-)-α-Methylhistamine dihydrobromide can enhance memory retention, attenuates memory impairment in rats .
    (R)-(-)-α-Methylhistamine dihydrobromide
  • HY-100784
    Dihydrokainic acid

    Dihydrokainic acid (DHK) is a glutamate transporter GLT1 (EAAT2) inhibitor. Dihydrokainic acid impairs novel object recognition (NOR) memory performance in mice. Dihydrokainic acid also shows epileptogenic effects .
    Dihydrokainic acid
  • HY-P2497
    Exendin (5-39)
    1 Publications Verification

    		 GCGR Neurological Disease
    Exendin (5-39) is a potent glucagon-like peptide 1 (GLP-1) receptor antagonist. Exendin (5-39) improves memory impairment in β-amyloid protein-treated rats .
    Exendin (5-39)
  • HY-15114
    S 17092

    S 17092-1

    		 Prolyl Endopeptidase (PREP) Neurological Disease
    S 17092 (S 17092-1) is a potent cerebral prolyl-endopeptidase (PEP) inhibitor with an IC50 of 1.2 nM. S 17092 can be used for the research of memory impairment and cognitive disorders associated with cerebral aging .
    S 17092
  • HY-N0691
    Schisandrin
    2 Publications Verification

    Schizandrin; Schizandrol; Schizandrol-A

    		 Autophagy Inflammation/Immunology Cancer
    Schisandrin (Schizandrin), a dibenzocyclooctadiene lignan, is isolated from the fruit of Schisandra chinensis Baill. Schisandrin exhibits antioxidant, hepatoprotective, anti-cancer and anti-inflammatory activities. Schisandrin also can reverses memory impairment in rats .
    Schisandrin
  • HY-N9410
    Lysophosphatidylcholine 18:2

    1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC

    		 Endogenous Metabolite Metabolic Disease
    Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary syndrome (PCOS). Low plasma Lysophosphatidylcholine 18:2 also has been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment .
    Lysophosphatidylcholine 18:2
  • HY-153416
    QR-0217

    		Amyloid-β Neurological Disease
    QR-0217 is a potent Aβ1-40 aggregation inhibitor with an IC50 value of 7.5 µM. QR-0217 inhibits α-synuclein aggregation. QR-0217 reduces memory impairments caused by Aβ neurotoxicity .
    QR-0217
  • HY-N4268
    Tenuifoliside B

    		Others Neurological Disease
    Tenuifoliside B, a component isolated from Polygalae Radix, inhibits potassium cyanide (KCN)-induced hypoxia and scopolamine-induced memory impairment. Tenuifoliside B shows potential cognitive improvement and cerebral protective effects. Tenuifoliside B has potential to become an anti-AD lead compound .
    Tenuifoliside B
  • HY-113616A
    VU0364572 TFA

    		mAChR Neurological Disease
    VU0364572 TFA is an orally active and selective allosteric agonist of the M1 muscarinic receptor with an EC50 of 0.11 μM. VU0364572 TFA has neuroprotective potential for preventing memory impairments and reducing neuropathology in Alzheimer’s Disease. VU0364572 TFA is CNS penetrant .
    VU0364572 TFA
  • HY-120782
    Yhhu-3792

    		Notch Neurological Disease
    Yhhu-3792 enhances the self-renewal capability of neural stem cells (NSCs). Yhhu-3792 activates Notch signaling pathway and promotes the expression of Hes3 and Hes5. Yhhu-3792 expands the NSCs pool and promotes endogenous neurogenesis in the hippocampal dentate gyrus (DG) in mouse. Yhhu-3792 increases the spatial and episodic memory abilities of mice. Yhhu-3792 has the potential for the research of impairment of learning and memory associated DG dysfunction .
    Yhhu-3792
  • HY-120782A
    Yhhu-3792 hydrochloride

    		Notch Neurological Disease
    Yhhu-3792 hydrochloride enhances the self-renewal capability of neural stem cells (NSCs). Yhhu-3792 hydrochloride activates Notch signaling pathway and promotes the expression of Hes3 and Hes5. Yhhu-3792 hydrochloride expands the NSCs pool and promotes endogenous neurogenesis in the hippocampal dentate gyrus (DG) in mouse. Yhhu-3792 hydrochloride increases the spatial and episodic memory abilities of mice. Yhhu-3792 hydrochloride has the potential for the research of impairment of learning and memory associated DG dysfunction .
    Yhhu-3792 hydrochloride
  • HY-P2712
    Chemerin-9, mouse

    Chemerin148–156, mouse

    		 Chemerin Receptor Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Chemerin-9, mouse (Chemerin148-156, mouse) is a C-terminal nonapeptide of chemerin. Chemerin-9, mouse is a ligand for ChemR23 (EC50 = 42 nM). Chemerin-9, mouse reduces basal lipolysis in primary mouse white adipocytes(IC50 = 3.3 nM). Chemerin-9, mouse enhances memory and relieves Aβ1-42-induced memory impairment in AD mice. Chemerin-9, mouse also inhibits atherogenesis .
    Chemerin-9, mouse
  • HY-P1025
    M40

    		Neuropeptide Y Receptor Cardiovascular Disease Neurological Disease
    M40 is an antagonist or a weak agonist for galanin receptor depending on different subtypes of galanin receptors in the brain, hypothalamus, hippocampus, amygdala and pancreas .
    M40
  • HY-P1025A
    M40 TFA

    		Neuropeptide Y Receptor Cardiovascular Disease Neurological Disease
    M40 TFA is the TFA salt form of M40. M40 TFA is an antagonist or a weak agonist for galanin receptor depending on different subtypes of galanin receptors in the brain, hypothalamus, hippocampus, amygdala and pancreas .
    M40 TFA
  • HY-15522
    WAY-267464

    		Oxytocin Receptor Neurological Disease
    WAY-267464 is a non-peptide oxytocin receptor (OTR) agonist. WAY-267464 can impair social recognition memory in rats through a vasopressin 1A receptor antagonist action. WAY-267464 can be used for the research of psychiatric disorders, such disorders include autism spectrum disorder, schizophrenia, and social anxiety disorder .
    WAY-267464
  • HY-131892
    2-Deoxy-D-galactose

    		Others Metabolic Disease Cancer
    2-Deoxy-D-galactose is a glucose analog. 2-Deoxy-D-galactose inhibits glycolysis to inhibits tumor growth. 2-Deoxy-D-galactose is a substance interfering with the fucosylation of glycomacromolecules and impairing memory consolidation in various learning tasks. 2-Deoxy-d-galactose hinders glycoprotein fucosylation in vivo .
    2-Deoxy-D-galactose
  • HY-155823
    TZ4M

    		Cholinesterase (ChE) Neurological Disease
    TZ4M is a 2,4-thiazolidinedione (TZD)-based anti-ADV agent with neuroprotective effects. TZ4M exhibits AChE inhibition in human plasma. TZ4M improves memory and cognitive impairment in adult rats in a scopolamine (HY-N0296)-induced Alzheimer-type model .
    TZ4M
  • HY-155822
    TZ3O

    		Cholinesterase (ChE) Neurological Disease
    TZ3O (compound TZ30) is an anticholinergic agent with neuroprotective effects. TZ3O (2 mg/kg, 4 mg/kg) can improve memory impairment and cognitive decline in rats in the Scopolamine (HY-N0296)-induced Alzheimer-type model. TZ3O could be used in Alzheimer’s research .
    TZ3O
  • HY-108679
    WAY-267464 hydrochloride

    		Oxytocin Receptor Neurological Disease
    WAY-267464 hydrochloride is a non-peptide oxytocin receptor (OTR) agonist. WAY-267464 hydrochloride can impair social recognition memory in rats through a vasopressin 1A receptor antagonist action. WAY-267464 hydrochloride can be used for the research of psychiatric disorders, such disorders include autism spectrum disorder, schizophrenia, and social anxiety disorder .
    WAY-267464 hydrochloride
  • HY-146086
    Nrf2 activator-4

    		Keap1-Nrf2 Reactive Oxygen Species Neurological Disease Inflammation/Immunology
    Nrf2 activator-4 (Compound 20a) is a highly potent, orally active Nrf2 activator with an EC50 of 0.63 µM. Nrf2 activator-4 suppresses reactive oxygen species against oxidative stress in microglia. Nrf2 activator-4 effectively recovers the learning and memory impairment in a scopolamine-induced mouse model .
    Nrf2 activator-4
  • HY-N1876
    Aromadendrane-4β,10α-diol

    Aromadendrane-4β,10α-diol is a sesquiterpene alcohol. Aromadendrane-4β,10α-diol significantly ameliorates the Aβ1-42 peptide-induced memory impairment. Aromadendrane-4β,10α-diol can be used for Alzheimer's disease (AD) research .
    Aromadendrane-4β,10α-diol
  • HY-149984
    MAO-B-IN-21

    		Monoamine Oxidase Neurological Disease Inflammation/Immunology
    MAO-B-IN-21 is an excellent MAO-B inhibitor with antioxidant activity and anti-Aβ aggregation activity. MAO-B-IN-21 also exhibits metal-ion chelating ability, anti-neuroinflammation (NO, TNF-α), neuroprotective activity and BBB permeability. MAO-B-IN-21 significantly improves the memory and cognitive impairment in Aβ1-42 induced Alzheimer's disease mice model .
    MAO-B-IN-21
  • HY-116377
    DU-14

    		Steroid Sulfatase Neurological Disease
    DU-14 is a potent steroid sulfatase inhibitor with an IC50 of 55.8 nM. DU-14 inhibits the MCF-7 cell proliferation (IC50 = 38.7 nM). DU-14 has neuroprotective effects against neurotoxic Aβ, suggesting that up-regulation of endogenous DHEAS by DU-14 could be beneficial to the alleviation of Aβ-induced impairments in spatial memory and synaptic plasticity .
    DU-14
  • HY-105066
    Davunetide

    		Microtubule/Tubulin Amyloid-β Neurological Disease
    Davunetide is an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP), a neurotrophic factor that exists in the mammalian CNS. Davunetide possesses neuroprotective, neurotrophic and cognitive protective roperties. Davunetide, a microtubule-stabilizing peptide, interacts with and stabilises neuron-specific βIII-tubulin in vitro. Davunetide penetrates the blood-brain barrier and is non-toxic. Davunetide inhibits Aβ aggregation and Aβ-induced neurotoxicity .
    Davunetide
  • HY-139973
    OAB-14

    		Amyloid-β Neurological Disease
    OAB-14, is a Bexarotene (HY-14171) derivative, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice. OAB-14 effectively ameliorates the dysfunction of the endosomal-autophagic-lysosomal pathway in APP/PS1 transgenic mice .
    OAB-14
  • HY-163382
    Cbz-Gly-Pro-Ala-O-cinnamyl

    		Beta-lactamase Cholinesterase (ChE) Amyloid-β Neurological Disease
    Cbz-Gly-Pro-Ala-O-cinnamyl (compound 25) is a small peptide targeting BACE-1 and AChE with the IC50 values of 0.02 μM and 1 μM, respectively. Cbz-Gly-Pro-Ala-O-cinnamyl shows neuroprotective effect and can be used for study of Alzheimer’s disease .
    Cbz-Gly-Pro-Ala-O-cinnamyl
  • HY-11068
    SB 239063
    Maximum Cited Publications
    26 Publications Verification

    		 p38 MAPK Autophagy Inflammation/Immunology
    SB 239063 is a potent, selective and orally active p38 MAPK inhibitor, exhibits an IC50 of 44 nM for recombinant purified human p38α, with equipotent inhibitory activity against p38α and p38β. SB 239063 has no effect on p38γ or p38δ. With anti-asthma activity and also be used to enhance memory which is impaired due to aging or medical conditions, such as, AD .
    SB 239063
  • HY-155992
    WLB-89462

    		Sigma Receptor Neurological Disease
    WLB-89462 (Compound 20c) is a selective σ2 receptor ligand (Ki: 13 nM). WLB-89462 has neuroprotective activity. WLB-89462 improves short-term memory impairment induced by Aβ peptide in rats. WLB-89462 has good ADMET profile (good solubility, no CYP inhibition, good metabolic stability, high permeability, brain penetration, and high oral exposure in rodents) .
    WLB-89462
  • HY-16361A
    Omigapil maleate

    CGP3466B; CGP3446 maleate; TCH346 maleate
    Omigapil maleate, an orally bioavailable GAPDH nitrosylation inhibitor, abrogates Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil maleate has the potential for the research of Alzheimer's disease . Omigapil maleate (CGP3446B maleate) is a apoptosis inhibitor. Omigapil maleate can be used for the research of congenital muscular dystrophy (CMD) . Omigapil (maleate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Omigapil maleate
  • HY-146005
    Tau-aggregation and neuroinflammation-IN-1

    		Microtubule/Tubulin Neurological Disease Inflammation/Immunology
    Tau-aggregation and neuroinflammation-IN-1 is a potent tau-aggregation and neuroinflammation inhibitor. Tau-aggregation and neuroinflammation-IN-1 exhibits remarkable inhibitory activities against AcPHF6 and full-length tau aggregation. Tau-aggregation and neuroinflammation-IN-1 has a low cytotoxicity and reduced NO release in LPS-stimulated BV2 cells. Tau-aggregation and neuroinflammation-IN-1 can reverse okadaic acid-induced memory impairment in rats .
    Tau-aggregation and neuroinflammation-IN-1
  • HY-153369
    BAY-747

    		Guanylate Cyclase Cardiovascular Disease Neurological Disease
    BAY-747 is an orally active and brain-penetrant stimulator of soluble guanylate cyclase (sGC). BAY-747 reverses L-NAME induced memory impairments and enhances cognition of rats in the object location task (OLT). BAY-747 also decreases blood pressure in both conscious normotensive and spontaneously hypertensive rats (SHR). BAY-747 improves function of the skeletal muscle associated with Duchenne muscular dystrophy (DMD) in mdx/mTRG2 mice model .
    BAY-747
  • HY-N6074
    Soyasapogenol B

    		Autophagy Apoptosis Inflammation/Immunology Cancer
    Soyasapogenol B is a component of soy that has oral activity. Soyasapogenol B promotes autophagy and apoptosis. Soyasapogenol B has anti-inflammatory, antioxidant and antitumor activities .
    Soyasapogenol B
  • HY-155733
    AChE/Aβ-IN-1

    		iGluR Cholinesterase (ChE) Amyloid-β Neurological Disease
    AChE/Aβ-IN-1 (compound 32) is a potent and orally active inhibitor of acetylcholinesterase (AChE) with an IC50 of 86 nM, as well as an antagonist of NMDA receptor (GluN1-1b/GluN2B subunit combination) with IC50 of 3.876 μM. AChE/Aβ-IN-1 also inhibits Aβ aggregation and shows good blood-brain barrier permeability and neuroprotection. AChE/Aβ-IN-1 improves cognitive and spatial memory impairment in rats model .
    AChE/Aβ-IN-1
  • HY-155735
    AChE/Aβ-IN-2

    		iGluR Cholinesterase (ChE) Amyloid-β Neurological Disease
    AChE/Aβ-IN-2 (compound 33) is a potent and orally active inhibitor of acetylcholinesterase (AChE) with IC50 of 135 nM, as well as an antagonist of NMDA receptor (GluN1-1b/GluN2B subunit combination) with IC50 of 5.054 μM. AChE/Aβ-IN-2 also inhibits Aβ aggregation and shows good blood-brain barrier permeability. AChE/Aβ-IN-2 improves cognitive and spatial memory impairment in rats model .
    AChE/Aβ-IN-2
  • HY-136094
    SRT3657

    		Sirtuin Neurological Disease
    SRT3657 is a brain-permeable activator of SIRT1, with neuroprotective effect .
    SRT3657
  • HY-116673
    TTK21

    		Histone Acetyltransferase Neurological Disease
    TTK21 is an activator of the histone acetyltransferases CBP/p300. TTK21 passes the blood–brain barrier, induces no toxicity, and reaches different parts of the brain when conjugated to glucose-based carbon nanosphere (CSP). TTK21 has beneficial implications for the brain functions of neurogenesis and long-term memory .CSP-TTK21 can ameliorate Aβ-impaired long-term potentiation (LTP). CSP-TTK21 may enhance the transcription of genes that promote synaptic health and cognitive function . CSP-TTK21 is orally effective and leads to improvements in motor functions, histone acetylation dynamics in a spinal injury rat model .
    TTK21
  • HY-N0006
    Demethoxycurcumin
    3 Publications Verification

    Curcumin II; Desmethoxycurcumin; Monodemethoxycurcumin

    		 Apoptosis Bacterial Cholinesterase (ChE) NO Synthase Infection Neurological Disease Inflammation/Immunology Cancer
    Demethoxycurcumin is one of the main active ingredients of curcumin, which has anti-inflammatory, antioxidant, antibacterial, anti-cancer and neuroprotective effects. Demethoxycurcumin is orally active. Demethoxycurcumin can be used in inflammation, cancer and Alzheimer's disease research .
    Demethoxycurcumin
  • HY-145833A
    sEH/AChE-IN-4

    		Epoxide Hydrolase Cholinesterase (ChE) Neurological Disease Cancer
    sEH/AChE-IN-4 (compound (+)-15) is a potent and BBB-penetrated dual inhibitor of sEH (soluble epoxide hydrolase) and AChE (acetylcholinesterase), with IC50 values of 3.1 nM (hsEH), 1660 nM (hAChE), 179 nM (hBChE, human butyrylcholinesterase), 14.5 nM (msEH), and 102 nM (mAChE), respectively .
    sEH/AChE-IN-4
  • HY-145833
    sEH/AChE-IN-3

    		Epoxide Hydrolase Cholinesterase (ChE) Neurological Disease Cancer
    sEH/AChE-IN-3 (compound (−)-15) is a potent and BBB-penetrated dual inhibitor of sEH (soluble epoxide hydrolase) and AChE (acetylcholinesterase), with IC50 values of 0.4 nM (hsEH), 1.94 nM (hAChE), 615 (hBChE, human butyrylcholinesterase), 4.3 nM (msEH), and 2.61 nM (mAChE), respectively .
    sEH/AChE-IN-3
  • HY-B0402A
    Amantadine hydrochloride
    2 Publications Verification

    1-Adamantanamine hydrochloride; 1-Adamantylamine hydrochloride; 1-Aminoadamantane hydrochloride

    		 Influenza Virus Orthopoxvirus SARS-CoV Apoptosis Bcl-2 Family CDK Infection Neurological Disease Cancer
    Amantadine (1-Adamantanamine) hydrochloride is an orally avtive and potent antiviral agent with activity against influenza A viruses. Amantadine hydrochloride inhibits several ion channels such as NMDA and M2, and also inhibits Coronavirus ion channels. Amantadine hydrochloride also has anti-orthopoxvirus and anticancer activity. Amantadine hydrochloride can be used for Parkinson's disease, postoperative cognitive dysfunction (POCD) and COVID-19 research .
    Amantadine hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: